Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
Nan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Haitao Zhao(Huaiyin Normal University), Hanping Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhenhui Lu(Shenzhen Sixth People's Hospital), Ziyu Xun(Chinese Academy of Medical Sciences & Peking Union Medical College), Longhao Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xinmu Zhang(Anhui Jianzhu University), Shanshan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Xu(Tianjin Medical University), Yanyu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mingjian Piao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaobo Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiashuo Chao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yunchao Wang(Shenzhen University), Cong Ning(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 82
Related Papers
Evaluation of cell-free DNA approaches for multi-cancer early detection
|Cancer Cell|2022|311
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
|Signal Transduction and Targeted Therapy|2023|289
Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis
|Journal of Hepatology|2014|186
Ser18 and 23 phosphorylation is required for p53‐dependent apoptosis and tumor suppression
|The EMBO Journal|2006|154